9 results
Optimizing orthotic management in children with cerebral palsy to improve mobility and participation
The primary objective of this study is to evaluate AFO efficacy in children with spastic CP using outcome measures related to ICF the components of *body functions and structures* and *activities and participation*. The secondary aim is to identify…
In this study the effectiveness of an ankle-foot orthosis on the walking ability and coordination in patients with Huntington's disease will be evaluated. Subject will be the question of the clinical relevance of wearing an AFO according to…
This study will consist of two parts. In the primary observational part we will assess kinematic and kinetic walking patterns in Duchenne Muscular Dystrophy. Goal is to asses the correlation between progressive contractures and gait patterns. This…
The objective of the study (phase 2) is to evaluate the effectiveness of AMG 102 in combination with Mitoxantrone and Prednisone in previously treated subjects with castrate resistant prostate cancer.
A new formulation of DuoTrav® eye drops, called DuoTrav APS, in which, the preservative (BAC) has been replaced by a new preservative called POLYQUAD has been developed. POLYQUAD is expected to be better tolerated in the eye, especially for the…
To determine whether AFOs optimized for stiffness in patients with calf muscle weakness are superior to standard AFOs in reducing walking effort, as measured by energy cost of walking (ECW, in Jkg-1m-1), and 2) to build a model to predict required…
Quizartinib selectively inhibits survival pathways that block apoptosis by inhibiting FLT3. Quizartinib inhibits proliferation of FLT3-dependent cell lines, and is effective in human leukemia tumor xenograft models of AML. Data from the Phase 1 and…
The primary aim of the NOPHO-DBH AML 2012 study is to improve EFS and OS in children with AML. To improve outcome, an intensified induction regimen will be given and a response guided risk-group stratification using flow cytometric minimal residual…
Primary objective:To evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute…